Insilico Medicine to Announce 2025 Financial Results

Got story updates? Submit your updates here. ›

Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence for drug discovery and development, announced that it will report its financial results for the year ended December 31, 2025, and provide a business update on March 30, 2026. The company will hold live conference calls in English and Mandarin on the same day.

Why it matters

Insilico Medicine is a prominent player in the AI-driven drug discovery and development space, and its financial performance and business updates are closely watched by investors and industry analysts. The announcement of its 2025 results will provide insights into the company's progress and future prospects.

The details

The English session of the conference call will be held at 9:00 AM on March 30, 2026, Beijing Time (9:00 PM U.S. Eastern Time on March 29, 2026), and the Mandarin session will be held at 10:30 AM Beijing Time on the same day (10:30 PM U.S. Eastern Time on March 29, 2026). Participants are required to pre-register for the conference calls using the provided links.

• Insilico Medicine will report its 2025 financial results on March 30, 2026.
• The English conference call will be held at 9:00 AM Beijing Time on March 30, 2026 (9:00 PM U.S. Eastern Time on March 29, 2026).
• The Mandarin conference call will be held at 10:30 AM Beijing Time on March 30, 2026 (10:30 PM U.S. Eastern Time on March 29, 2026).

What’s next

Investors and analysts will be closely following Insilico Medicine's 2025 financial results and business update on March 30, 2026 to assess the company's performance and future prospects.